US pharma major Eli Lilly on Thursday launched the much-awaited diabetes and obesity management drug Mounjaro (tirzepatide) in India, priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial.
The drug, usually taken once a week, would then cost between ₹14,000 and ₹17,500 per month, depending on the dosage recommended by the doctor. The average monthly price of Mounjaro in the US is around $1,000–$1,200 (approximately ₹86,000–1 lakh).